Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CS1 HLE BiTE
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BCMA-CS1 HLE BiTE is a dual-targeting bispecific T-cell engager (BiTE) developed by Amgen for the treatment of multiple myeloma. This immunotherapy agent is designed to simultaneously engage two tumor-associated antigens (TAAs) on cancer cells—B-cell maturation antigen (BCMA) and CS1 (also known as SLAMF7)—while binding to CD3ε on T cells. By bridging these targets, the molecule redirects the patient's T cells to induce lysis of the tumor cells. The molecule also incorporates an Fc-based domain to provide half-life extension (HLE), allowing for less frequent dosing compared to first-generation BiTE molecules. This dual-targeting approach is intended to overcome challenges such as heterogeneous antigen expression and potential antigen loss that can limit the efficacy of therapies targeting BCMA alone.
- Other names
- dual-targeting BCMA-CS1 HLE BiTE molecule
02
Targets
BCMA (B-cell maturation antigen)CD3E (T-cell surface glycoprotein CD3 epsilon chain)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on BCMA-CS1 HLE BiTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CS1 HLE BiTE.